CATALYSTYahoo • 5d ago
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsLilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
Why GPCR Stock surged +2.14% Today — RQD Quant Desk Flash
$21.94 +2.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.98
Structure Therapeutics Inc. (GPCR) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.56B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GPCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GPCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Structure Therapeutics Inc. (NASDAQ: GPCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $21.94 (+2.14% 1D, market cap $1.56B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GPCR ranks #918 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GPCR compare to PAHC and INVA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GPCR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -19.5%. By comparison, PAHC (Phibro Animal Health Corporation (Class A)) holds a D+ grade (56/100 RQD, P/E 32.7x, ROIC 9.9%, cap $1.58B) and INVA (Innoviva Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GPCR?
▼
Per GPCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001888886), Structure Therapeutics Inc. generated $0 in revenue, -$141.2M in net income, and -$225.8M in free cash flow against $1.58B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.98 (+0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GPCR)Realized 20D OHLCV Swing Band: ±11.8%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY GPCR SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (37% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.1 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$23.91-7.9% Next Q
35
Q2 (-2Q)Grade E$22.01-4.1% Next Q
32
Q3 (-1Q)Grade E$21.10+4% Next Q
30
CurrentGrade E$21.94-10.3% Hist 90D α
27
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GPCR Turnaround Squeeze
While GPCR currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.89) and Max Pain ($23.04) forces dealer call-delta covering toward $99.65.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GPCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GPCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GPCR Stock surged +2.14% Today — RQD Quant Desk Flash
Structure Therapeutics Inc. (GPCR) surged +2.14% to $21.94, trading at 2% of its 52-week range ($20.5 – $94.9). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($20.5 – $94.9) with RSI-14 at 27.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.8% around $21.94 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GPCR Headlines & Catalysts
CATALYSTYahoo • 11d ago
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
MARKET WIREYahoo • 13d ago
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, wit
CATALYSTYahoo • 13d ago
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GPCR)
- ✓Walkthrough of GPCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GPCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.02%🛡️ HOLDING TREND SUPPORT
2026-11-02O $21.48H $21.94L $21.48C $21.94VOL 929.5K
RES: $53.00SUP: $19.15SMA50: $32.89SMA200: $48.74
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GPCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GPCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GPCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GPCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GPCR)
Health Care Rank #918 of 1016
⚔️ PAHC vs GPCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GPCR vs. PAHC, INVA, ETON, OCUL)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Structure Therapeutics Inc. (GPCR) ranks #918 by composite RQD confidence (27/100, grade E) and #301 by equity capitalization ($1.56B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with GPCR at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GPCR
ACTIVE
Structure Therapeutics Inc. | E | 27/100 | — | — | -19.5% | +2.14% | $1.56B | Benchmark Subject |
| PAHC Phibro Animal Health Corporation (Class A) | D+ | 56/100 | 32.7x | 30.9% | 9.9% | +2.59% | $1.58B | /pahc-vs-gpcr → |
| INVA Innoviva Inc. | C+ | 67/100 | — | 74.8% | 14.7% | +0.90% | $1.54B | /inva-vs-gpcr → |
| ETON Eton Pharmaceuticals Inc. | D+ | 58/100 | — | 53.5% | -0.9% | +3.61% | $1.53B | /eton-vs-gpcr → |
| OCUL Ocular Therapeutix Inc. | E | 25/100 | — | 87.3% | -35.0% | +0.27% | $1.61B | /ocul-vs-gpcr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001888886In its most recent audited fiscal period (FY2025, filed 2025-12-31), Structure Therapeutics Inc. (GPCR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$141.2M, operating cash flow of -$222.2M, and free cash flow of -$225.8M (-91.5% YoY). On the balance sheet, GPCR closed FY2025 with $1.58B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$141.2M | -$222.2M | -$225.8M | $1.58B | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$122.5M | -$116.6M | -$117.9M | $903.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$89.6M | -$79.5M | -$79.5M | — | — |
3. GPCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GPCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Structure Therapeutics Inc. (NASDAQ: GPCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $21.94 (+2.14% 1D, market cap $1.56B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GPCR ranks #918 in composite RQD confidence.
How does GPCR compare to PAHC and INVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GPCR carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -19.5%. By comparison, PAHC (Phibro Animal Health Corporation (Class A)) holds a D+ grade (56/100 RQD, P/E 32.7x, ROIC 9.9%, cap $1.58B) and INVA (Innoviva Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GPCR?
Per GPCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001888886), Structure Therapeutics Inc. generated $0 in revenue, -$141.2M in net income, and -$225.8M in free cash flow against $1.58B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GPCR trading relative to its 50-day, 200-day, and 52-week technical levels?
GPCR last traded at $21.94 (+2.14% on volume of 929,537 shares), positioning the stock -33.29% below its 50-day simple moving average ($32.89) and -54.99% below its 200-day simple moving average ($48.74). Across its 52-week range of $20.50 to $94.90, GPCR sits at the 1.9% percentile with a 14-day RSI of 27.1 (OVERSOLD (<32)) and an implied next-earnings move of ±11.8% ($19.35 to $24.53).
GPCR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GPCR stock moving today?
Why GPCR Stock surged +2.14% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.